Final Report on the Aspirin Component of the Ongoing Physicians' Health Study

New England Journal of Medicine

Volumn 321, Issue 3, 1989, Pages 129-135

 

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

CLINICAL TRIAL; CONTROLLED STUDY; HEART INFARCTION; HUMAN; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHOLESTEROL; CLINICAL TRIALS; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMAN; MIDDLE AGE; MYOCARDIAL INFARCTION; PEPTIC ULCER; PHYSICIANS; RANDOM ALLOCATION; RISK; SUPPORT, U.S. GOV'T, P.H.S.; UNITED STATES;

EID: 0024406369     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198907203210301     Document Type: Article

References (21)

1. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979; 300: 1142–7.
2. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J 1988; 296: 316–20.
3. Jick H, Miettinen OS. Regular aspirin use and myocardial infarction. Br Med J 1976; 1: 1057.
4. Hennekens CH, Karlson LK, Rosner B. A case–control study of regular aspirin use and coronary deaths. Circulation 1978; 58: 35–8.
5. Hammond EC, Garfinkel L. Aspirin and coronary heart disease: findings of a prospective study. Br Med J 1975; 2: 269–71.
6. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown, 1987.
7. Friedewald WT. Aspirin and coronary deaths. Circulation 1978; 58: 39–40.
8. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585–612.
9. The Steering Committee of the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988; 318: 262–4.
10. Stampfer MJ, Buring JE, Willett W, Rosner B, Eberlein K, Hennekens CH. The 2x2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians. Stat Med 1985; 4: 111–6.
11. World Health Organization. Ischaemic heart disease registers: report of the Fifth Working Group, including a second revision of the operating protocol: Copenhagen, 26–29 April 1971. Copenhagen, Denmark: Regional Office for Europe, World Health Organization, 1971.
12. Kleinbaum D, Kupper L, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, Calif.: Lifetime Learning Publications, 1982:336.
13. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 13–6.
14. Hennekens CH, Peto R, Hutchison GB, Doll R. An overview of the British and American aspirin studies. N Engl J Med 1988; 318: 923–4.
15. Aspirin for heart patients. FDA Drug Bull 1985; 15: 34–6.
16. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320–31.
17. ISIS–2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
18. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243: 661–9.
19. Stampfer MJ, Jakubowski JA, Deykin D, Schafer AI, Willett WC, Hennekens CH. Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and THROMBOXANE A2 levels in bleeding-time blood. Am J Med 1986; 81: 400–4.
20. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177–84.
21. Aspirin for TIA's. FDA Drug Bull 1980; 10: 2.